Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit?
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Nicola Gray, Royal Sussex County Hospital
First received: September 5, 2011
Last updated: April 5, 2016
Last verified: April 2016
Birch pollen allergy is increasingly common. It causes asthma and early season hay fever. This is because the body recognises birch pollen and reacts to it, leading to symptoms. Many patients with birch allergy get an itchy and/or swollen mouth when they eat fresh fruit (apples, pears, peaches, plums etc). Some fruit proteins have a similar structure to birch pollen; because of this the body recognises these proteins too causing the immune system to respond. This response causes symptoms of itch and swelling inside the mouth and throat. the investigators want to find out whether it is possible to get rid of the fruit-induced symptoms by using a desensitisation procedure that has been developed for treating the kind of hay fever that is caused by birch pollen. Desensitisation involves giving a small injection of pollen just under the skin and gradually increasing the amount each week. This allows the body to build up a "tolerance" to the injected protein. When the pollen is then encountered in real life the immune system reacts less vigorously so symptoms are less severe. This treatment does reduce hay fever symptoms. Our study aims to find out if this tolerance is transferred to the fruit proteins enabling patients to eat apples with minimal symptoms. Patients will be given apple to eat in a hidden form before treatment and their response assessed. They will then receive either active or dummy pollen injections before birch pollen season. A few months after completing these injections they will have another disguised apple test to see whether their symptoms are any better. If symptoms have improved with treatment then this therapy could be offered to patients in the future. This would allow them to eat fresh fruit without worrying about unpleasant symptoms and improve their hay fever symptoms.
Oral Allergy Syndrome
Biological: Allergovit Birch pollen
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
||A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients
Primary Outcome Measures:
- Change in threshold for eating uncooked apple from baseline, compared to 1 year and 2 years following the intervention. [ Time Frame: baseline, 1 year and 2 years ] [ Designated as safety issue: No ]
Baseline measurements will be taken in Winter 2012 assessing the tolerance to fresh apple in a double blind placebo controlled manner. The intervention will start in January 2013.
Outcomes will be assessed using the double blind placebo controlled food challenge technique in Winter 2013 and 2014. (1 and 2 years after baseline assessment)
Secondary Outcome Measures:
- Change in symptoms of rhinoconjunctivitis immediately after the first season of immunotherpay compared to 2 seasons of immunotherapy treatment. [ Time Frame: baseline, 1 year and 2 years ] [ Designated as safety issue: No ]
Diary cards will be given to patients to complete in the first season following immunotherapy, to assess hay fever symptoms.
- Change in conjunctival provocation tests from baseline. [ Time Frame: baseline, 1 year and 2 years ] [ Designated as safety issue: No ]
Conjunctival provocation testing will take place at baseline in Winter 2012 using standard birch pollen exracts. Repeat tests will occur Winter 2013 and 2014 to assess changes following the intervention.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||November 2016 (Final data collection date for primary outcome measure)
Placebo Comparator: Subcutaneous injection of placebo
Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
Active Comparator: Birch pollen immunotherapy
Biological: Allergovit Birch pollen
Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
|Ages Eligible for Study:
||18 Years and older (Adult, Senior)
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male or female; age 18 with no upper age limit
- History of typical fruit-related symptoms on eating apples plus or minus other plant-derived foods known to be involved in the pollen-food syndrome
- History of spring rhinitis hay fever
- Positive skin prick test to birch pollen
- Positive open food challenge to apple
- Significant medical conditions that may affect the risks of giving BP-SIT (especially uncontrolled asthma or ongoing need for beta-blockers)
- History of moderate to severe systemic reaction to apple, defined as any of: generalised urticaria, generalised angioedema, history convincing for laryngeal oedema, collapse
- Current immunological disease (auto-immune or thyroid disease, immunodeficiency)
- Malignant disease within the past five years (Patients with previous malignant disease that is considered cured, may be included subject to the consent of their oncologist)
- Inability to attend regularly for injections and follow-up visits
- Severe atopic dermatitis
- Previous immunotherapy with birch pollen extract
- Pregnant or not using adequate contraception (post-menopausal, surgically sterilised, long-term abstinent, or barrier methods plus spermicide)
- Evidence of current drug or alcohol misuse
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01431859
|Royal Sussex County Hospital
|Brighton, East Sussex, United Kingdom, BN2 5BE |
Royal Sussex County Hospital
||Anthony Frew, MBBS MD FRCP
||Brighton and Sussex University Hospital Trust
||Nicola Gray, Clinical Research Fellow, Royal Sussex County Hospital
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 5, 2011
||April 5, 2016
||United Kingdom: Medicines and Healthcare Products Regulatory Agency
United Kingdom: Research Ethics Committee
Keywords provided by Royal Sussex County Hospital:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 28, 2016
Immune System Diseases